CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
5.15
-0.08 (-1.53%)
Nov 6, 2026, 11:56 AM EST - Market open
CorMedix Employees
CorMedix had 191 employees as of December 31, 2025. The number of employees increased by 126 or 193.85% compared to the previous year. That makes CorMedix the 27,131st largest employer in the world and 3,433rd in the United States.
Employees
191
Change (1Y)
126
Growth (1Y)
193.85%
Revenue / Employee
$2,420,152
Profits / Employee
$973,901
Market Cap
401.41M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 191 | 126 | 193.85% | 191 | 0 |
| Dec 31, 2024 | 65 | -18 | -21.69% | 64 | 1 |
| Dec 31, 2023 | 83 | 42 | 102.44% | 82 | 1 |
| Dec 31, 2022 | 41 | 11 | 36.67% | 40 | 1 |
| Dec 31, 2021 | 30 | -5 | -14.29% | 29 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Phathom Pharmaceuticals | 371 |
| Editas Medicine | 87 |
| Prelude Therapeutics | 79 |
| Prothena Corporation | 67 |
| Oculis Holding AG | 60 |
| Rezolute | 58 |
| Eupraxia Pharmaceuticals | 49 |
CRMD News
- 3 hours ago - CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 - GlobeNewsWire
- 4 days ago - CorMedix backs FY26 revenue view $325M-$345M, consensus $336.59M - TheFly
- 4 days ago - CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position - GlobeNewsWire
- 18 days ago - CorMedix announces FDA acceptance for Priority Review of Rezzayo sNDA - TheFly
- 18 days ago - Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases - GlobeNewsWire
- 22 days ago - Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer - PRNewsWire
- 6 weeks ago - CorMedix initiated with an Outperform at Oppenheimer - TheFly
- 1 month ago - CorMedix Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts